Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 13Breast 10Thoracic 7Genitourinary 6CNS 5Gynecologic 4Tumor-Agnostic 2Head & Neck 2Endocrine 2Dermatologic 2Lymphoid 1

Conditions

Melanoma 2Prostatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Sevoflurane × Dermatologic × Clear all
NCT04074460 2022-06-09

VAPOR-C

Peter MacCallum Cancer Centre, Australia

Phase 4 Completed
169 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Prostatic Neoplasms

NCT01588847 2014-12-11

Anesthesia and Cancer Recurrence im Malignant Melanoma

University Hospital Muenster

Phase NA Unknown
230 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡